-
Bayer strongly deploys Parkinson's innovative therapies, stem cell and gene therapy have entered the clinical stage, Yi Mai Meng broke the news
Time of Update: 2021-06-22
Recent popular reports from Yimaike ★ Invitation to the grand event 2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has been hundreds of millions in half a ye
-
Express treatment of Parkinson's disease, Bayer's innovative cell therapy and gene therapy enter clinical trials
Time of Update: 2021-06-17
At the same time, its subsidiary Asklepios Biopharmaceuticals (AskBio) is also advancing gene therapy for Parkinson's disease, and is currently recruiting and evaluating patients in an ongoing phase 1b clinical study .
-
Bayer's innovative cell therapy and gene therapy for the treatment of Parkinson's disease enter clinical trials
Time of Update: 2021-06-16
On June 8, 2021, Bayer announced that its BlueRock Therapeutics (BlueRock) company had successfully transplanted DA01, a dopaminergic neuron therapy produced by pluripotent stem cells, to a Parkinson’s disease in a phase 1 clinical trial.
-
Bayer promotes two first cell and gene therapies to treat Parkinson's disease
Time of Update: 2021-06-16
Bayer Group announced on June 8 that its wholly-owned clinical trial phase biopharmaceutical company BlueRock (BlueRock Therapeutics) has successfully completed the administration of a Parkinson’s disease patient in an open-label phase I clinical study.
-
Bayer's $335 million investment in gene programming start-up CRISPR has been awarded a joint human test
Time of Update: 2021-02-21
Bayer, the German pharmaceutical company valued at $96 billion, will invest at least $300 million over the next five years in CRISPRTherapeutics to develop CRISPR-cas9 gene programming technology to treat diseases such as blood disease, blindness and congenital heart disease.
-
Bayer buys gene therapy company AskBio for $4 billion
Time of Update: 2020-11-05
will first advance $2 billion to obtain a gene therapy platform for AskBio.
AskBio's adeno-related gene (AAV) treatment platform has shown potential in a variety of diseases, and the company's main research program focuses on Pompeia, Parkinson's disease and congestive heart failure.
-
Bayer $252 million plus hemophilia gene therapy
Time of Update: 2014-06-25
Source: China Council for the promotion of drugs June 23, 2014, Bayer announced that it would obtain the gene therapy project of dimension company for hemophilia treatment at the price of US $252 mill
